[Federal Register Volume 76, Number 24 (Friday, February 4, 2011)]
[Notices]
[Pages 6456-6457]
From the Federal Register Online via the Government Publishing Office [www.gpo.gov]
[FR Doc No: 2011-2487]


-----------------------------------------------------------------------

DEPARTMENT OF DEFENSE

Department of the Army


Intent To Grant an Exclusive License for a U.S. Government-Owned 
Invention

AGENCY: Department of the Army, DoD.

ACTION: Notice.

-----------------------------------------------------------------------

SUMMARY: In accordance with 35 U.S.C. 209(e), and 37 CFR 
404.7(a)(1)(i), announcement is made of the intent to grant an 
exclusive, revocable license, to U.S. Patent No. 6,254,873, issued July 
3, 2001, entitled ``Inactivated Dengue Virus Vaccine,'' for the field 
of use involving any prophylactic and/or therapeutic purified 
inactivated vaccine against Dengue virus for human use. The intended 
licensee is GlaxoSmithKline Bio, with its principal place of business 
at 89 Rue de l'Institut, 1330 Rixensart, Belgium.

ADDRESSES: Commander, U.S. Army Medical Research and Materiel Command, 
ATTN: Command Judge Advocate, MCMR-JA, 504 Scott Street, Fort Detrick, 
Frederick, MD 21702-5012.

FOR FURTHER INFORMATION CONTACT: For licensing issues, Dr. Paul Mele, 
Office of Research and Technology Applications (ORTA), (301) 619-6664. 
For patent issues, Ms. Elizabeth Arwine, Patent Attorney, (301) 619-
7808, both at telefax (301) 619-5034.

[[Page 6457]]


SUPPLEMENTARY INFORMATION: Anyone wishing to object to the grant of 
this license can file written objections along with supporting 
evidence, if any, within 15 days from the date of this publication. 
Written objections are to be filed with the Command Judge Advocate (see 
ADDRESSES).

Brenda S. Bowen,
Army Federal Register Liaison Officer.
[FR Doc. 2011-2487 Filed 2-3-11; 8:45 am]
BILLING CODE 3710-08-P